产后呋塞米加速子痫前期患者恢复:一项随机安慰剂对照试验
该三盲安慰剂对照随机试验纳入120例产后重度子痫前期或子痫患者,随机接受呋塞米40 mg/d口服5天或安慰剂。结果显示呋塞米组平均每日收缩压和舒张压更低(P<.001),产后第2天和第5天严重高血压发作更少(P=.04),血压控制所需时间更短(P=.01)。
要点
- 呋塞米40 mg/d口服5天可降低产后平均每日收缩压和舒张压(P<.001)。
- 呋塞米组产后第2天和第5天严重高血压发作次数更少(P=.04)。
- 呋塞米组血压控制所需时间更短(P=.01)。
核心结论
- 与安慰剂相比,子痫前期患者口服呋塞米40 mg/d可降低产后第1天和第5天平均每日收缩压、第1天、第2天和第5天平均每日舒张压以及血压控制所需时间。
研究设计与样本
- 三盲安慰剂对照随机临床试验,纳入产后新发重度子痫前期或子痫、利尿充分且接受过硫酸镁治疗的患者,随机接受呋塞米40 mg/d口服5天或安慰剂。
- 2014年6月20日至2014年11月30日筛查271例,随机120例,最终分析118例(呋塞米组58例,安慰剂组60例)。
- 样本量基于呋塞米组平均收缩压142±12 mm Hg与安慰剂组153±19 mm Hg的预估差异估算为120例,每组60例。
主要发现
- 呋塞米组平均每日收缩压和舒张压低于安慰剂组(P<.001)。
- 呋塞米组产后第2天(P=.04)和第5天(P=.04)严重高血压发作次数少于安慰剂组。
- 呋塞米组血压控制所需时间短于安慰剂组(P=.01)。
- 两组多数特征相似。
临床怎么用
- 作者结论认为,与安慰剂相比,子痫前期患者口服呋塞米40 mg/d可降低产后第1天和第5天平均每日收缩压、第1天、第2天和第5天平均每日舒张压及血压控制所需时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preeclampsia is a major hypertensive disorder of pregnancy that may lead to severe complications, particularly in the first 2 weeks of the postpartum period. Blood pressure during the postpartum period remains high and often increases to levels higher than those observed during pregnancy. Furosemide, a fast-acting diuretic, reduces intravascular volume overload and may represent an alternative to accelerate the normalization of blood pressure levels. OBJECTIVE: This study aimed to evaluate the effectiveness of furosemide compared with a placebo for blood pressure control in the postpartum period in women with severe preeclampsia. STUDY DESIGN: In a triple-masked placebo-controlled randomized clinical trial, postpartum women with de novo preeclampsia with severe features or eclampsia diagnosed during pregnancy and adequate diuresis who had received magnesium sulfate were randomized to receive furosemide (40 mg/d orally for 5 days) or a placebo. The primary outcome was mean blood pressure. The secondary outcomes were frequency of severe hypertensive episodes, continued need for antihypertensives, number of antihypertensives used to control blood pressure, length of hospital stay, adverse effects, and maternal complications. A sample size of 120 patients was estimated, 60 in each arm of the study, based on the estimated difference between the mean systolic pressure of 142±12 mm Hg for the furosemide group and 153±19 mm Hg for the placebo group. RESULTS: Between June 20, 2014, and November 30, 2014, 271 women were screened, and 120 were randomized to the furosemide or placebo groups, of which 118 were included in the final analysis (58 in the furosemide group and 60 in the placebo group). Most characteristics were similar between the groups. The mean daily systolic and diastolic pressures were lower in the furosemide group (P<.001), and there were fewer episodes of severe hypertension on the second (P=.04) and fifth (P=.04) days of the postpartum period. In addition, a shorter time was required until blood pressure was controlled (P=.01) in the furosemide group. CONCLUSION: Compared with placebo, 40 mg/d of oral furosemide in patients with preeclampsia reduced the mean daily systolic blood pressure in the first and fifth days of the postpartum period and mean daily diastolic blood pressure in the first, second, and fifth days of the postpartum period and the time required for blood pressure control. El resumen está disponible en Español al final del artículo.
引用
- Cursino T, Katz L, Coutinho I, et al. Postpartum furosemide for accelerating recovery in patients with preeclampsia: a randomized placebo-controlled trial. Am J Obstet Gynecol MFM. 2025. PMID: 39870324. doi:10.1016/j.ajogmf.2025.101614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。